TASK DEFINITION: Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
PROBLEM: Diamphidia nigroornata or Bushman arrow-poison beetle, is an African leaf beetle species in the genus Diamphidia.

SOLUTION: Is Diamphidia nigroornata a genus or species?

PROBLEM: Does everyone want a challenging job? In spite of all the attention focused by the media, academicians, and social scientists on human potential and the needs of individuals, there is no evidence to support that the vast majority of workers want challenging jobs. Some individuals prefer highly complex and challenging jobs; others develop in simple, routine work. The individual-difference variable that seems to gain the greatest support for explaining who prefers a challenging job and who doesn't is the strength of an individual's needs for personal growth and self-direction at work. Individuals with these higher-order growth needs are more responsive for challenging work. What percentage of ordinary workers actually desire higher-order need satisfactions and will respond positively to challenging jobs? No current data is available, but a study from the 1970s estimated the figure at about 15%. Even after adjusting for changing work attitudes and the growth in white-collar jobs, it seems unlikely that the number today exceeds 40%. The strongest voice advocating challenging jobs has not been workers--it's been professors, social science researchers, and media people. Professors, researchers, and journalists undoubtedly made their career choices, to some degree, because they wanted jobs that gave them autonomy, recognition and challenge. That, of course, is their choice. But for them, to force their needs onto the workforce in general is presumptuous . Not every employee is looking for a challenging job. Many workers meet their higher-order need off the job. There are 168 hours in every individual's week. Work rarely consumes more than 30% of this time. That leaves considerable opportunities, even for individuals with strong growth needs, to find higher-order need satisfaction outside the workplace. So don't feel you have a responsibility to create challenging jobs for all your employees. For many people, work is something that will never excite or challenge them. And they don't expect to find their growth opportunities at work. Work is merely something they have to do to pay their bills. They can find challenges outside of work on the golf course, fishing, at their local pub, with their friends in social clubs, with their family, and the like.

SOLUTION: What makes people choose challenging jobs?

PROBLEM: Normal B lymphocytes receive signals from B-cell antigen receptor (BCR) that are triggered by binding of the BCR to an external antigen. Tonic signaling through the BCR provides growth and signals to chronic lymphocytic leukemia (CLL) cells, and plays an important role in the pathogenesis and progression of the disease. Antigen engagement of BCR is followed by intracellular recruitment and activation of BCR-associated kinases including spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk) and phosphatidylinositol 3-kinases (PI3K). Inhibition of signaling pathways downstream of the BCR induces disruption of chemokine-mediated CLL cell migration and cell killing. BCR signal transduction inhibitors represent a promising new strategy for targeted CLL treatment. A number of therapeutic agents have recently been developed with significant activity in CLL. The compounds that are currently investigated in patients with CLL include ibrutinib -inhibitor of Btk, fostamatinib-inhibitor of Syk and idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. The clinical activity of ibrutinib, GS-1101 and fostamatinib in patients with CLL is associated with marked lymphocytosis due to release of tumor cells from the lymph nodes into the peripheral blood. Further studies are ongoing with single agents and their combinations with other targeted and conventional therapies. This article will review the preclinical rationale of BCR signaling inhibitors in the treatment of CLL, and the clinical evidence supporting the use of these agents in CLL patients.

SOLUTION:
What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?